PIC
TLX

Portland Investment Counsel’s Telix Pharmaceuticals TLX Stock Holding History

Portland Investment Counsel’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Hold
266,200
– – 0.82% 16
2025
Q4 		$2.06M Buy
266,200
+138,200
+108% +$1.33M 0.62% 19
2025
Q3 		$1.22M Buy
+128,000
New +$1.57M 0.34% 27

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Portland Investment Counsel's TLX Position: Q1 2026 in Review

Portland Investment Counsel held its Telix Pharmaceuticals (TLX) position steady in Q1 2026 at 266,200 shares worth $2.55M. The position accounts for 0.82% of the portfolio, ranked #16.

Portland Investment Counsel first reported a position in TLX in Q3 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Portland Investment Counsel held 266,200 shares of Telix Pharmaceuticals worth $2.55M as of Q1 2026.
  • Portland Investment Counsel left its Telix Pharmaceuticals share count unchanged in Q1 2026.
  • Telix Pharmaceuticals made up 0.82% of Portland Investment Counsel's portfolio in Q1 2026, its #16 holding.
  • Portland Investment Counsel first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Portland Investment Counsel's 13F filing for Q1 2026, filed 14 May 2026.